TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

businesswire

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer – NEWSnet – News… as it used to be

More Press Releases

May 30, 2026

SIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD’S LONGEST FAMILY LAUNCH ROLLER COASTER

May 30, 2026

VR/AR Content Brings Marine Engineering Courses to Life for Remote Students

May 30, 2026

Maxpeedingrods Strengthens Its Air Suspension Product Ecosystem with Expanded Solutions for Ride Comfort, Load Support, and Digital Air Control

May 30, 2026

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

SIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD’S LONGEST FAMILY LAUNCH ROLLER COASTER

VR/AR Content Brings Marine Engineering Courses to Life for Remote Students

Maxpeedingrods Strengthens Its Air Suspension Product Ecosystem with Expanded Solutions for Ride Comfort, Load Support, and Digital Air Control

Global Microcap Investors Are Discovering a Rare Diamond in the Rough